<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04528212</url>
  </required_header>
  <id_info>
    <org_study_id>fenofibrate vs curcumin</org_study_id>
    <nct_id>NCT04528212</nct_id>
  </id_info>
  <brief_title>Fenofibrate Versus Curcumin in Type 2 Diabetic Patients</brief_title>
  <official_title>Comparison of the Effect of Fenofibrate Versus Curcumin in Type 2 Diabetic Patients Treated With Glimepiride</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rehab Werida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damanhour University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effect of fenofibrate versus curcumin on glycemic&#xD;
      status, lipids profile, hs-CRP, sirtuin-1 and fetuin-A in type 2 diabetic patients who are&#xD;
      taking glimepiride.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Method &amp; Proposal Steps&#xD;
&#xD;
      1- Approval will be obtained from Research Ethics Committee of Faculty of Pharmacy, Damanhour&#xD;
      University. 2- All participants agreed to take part in this clinical study and provide&#xD;
      informed consent. 3- (60) Patients with DM type 2 who's taking Glimepiride will be enrolled&#xD;
      from Internal Medicine Department, Tanta University Hospital. 4- Serum samples will be&#xD;
      collected for measuring the biomarkers. 5- All enrolled patients will be mentioned as two&#xD;
      groups; Group I are patients who will be prescribed glimepiride plus fenofibrate. Group II&#xD;
      are patients who will be prescribed glimepiride plus curcumin. 6- All patients will be&#xD;
      followed up during 3 months' period. 7- At the end of 3 months on the new regimen, steps 4&#xD;
      will be repeated. 8- Statistical tests appropriate to the study design will be conducted to&#xD;
      evaluate the significance of the results. 9- Measuring outcome: The primary outcome is the&#xD;
      change of serum levels of the measured markers after 3 months and lipid profile. 10- Results,&#xD;
      conclusion, discussion and recommendations will be given.&#xD;
&#xD;
      Methodology Serum levels of fetuin-A, and Sirtuin1 (SIRT1) will be measured ELISA. Lipid&#xD;
      profile. Fasting Blood glucose and 2 hrs postprandial Blood Glucose. Hb A1C will be measured.&#xD;
      BMI of the patients will be measured before and after the study. High sensitivity C-reactive&#xD;
      protein (hs-CRP) will be measured.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fetuin-A (ng/ml)</measure>
    <time_frame>three months</time_frame>
    <description>human Fetuin A protein</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sirtuin1 (SIRT1) (ng/ml)</measure>
    <time_frame>three months</time_frame>
    <description>human Sirtuin1 a Protein - Recombinant human SIRT1 protein</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol (mg/dl)</measure>
    <time_frame>Three Months</time_frame>
    <description>Total Cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride (mg/dl)</measure>
    <time_frame>Three Months</time_frame>
    <description>Triglyceride</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glimepiride (4 mg) per Day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glimepiride (4 mg) plus Fenofibrate (160 mg) per Day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glimepiride (4 mg) plus Curcumin (1100 mg) With 5mg Black Pepper per Day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride Tablets</intervention_name>
    <description>Glimepiride (4 mg) per Day</description>
    <arm_group_label>Group I</arm_group_label>
    <other_name>Amaryl 4 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glimepiride plus fenofibrate</intervention_name>
    <description>Glimepiride (4 mg) plus Fenofibrate (160 mg) per Day</description>
    <arm_group_label>Group II</arm_group_label>
    <other_name>Amaryl 4 mg Plus Lipanthyl Supra (160 mg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glimepiride plus curcumin</intervention_name>
    <description>Glimepiride (4 mg) plus Curcumin (1100 mg) With 5mg Black Pepper per Day</description>
    <arm_group_label>Group III</arm_group_label>
    <other_name>Amaryl 4 mg Plus Curcumin (1100 mg) With 5mg Black Pepper</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  60 Patients with type 2 DM diagnosed clinically.&#xD;
&#xD;
          -  The age ranged from 35 to 70 years.&#xD;
&#xD;
          -  There are no limits to the duration of DM and gender.&#xD;
&#xD;
          -  HbA1c ≥ 7&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other types of DM&#xD;
&#xD;
          2. Hypersensitivity to the drug&#xD;
&#xD;
          3. Abnormal liver function&#xD;
&#xD;
          4. Patients with renal impairment (eGFR ≤ 60 ml/min)&#xD;
&#xD;
          5. Addition of any antidiabetic medications or insulin during follows up.&#xD;
&#xD;
          6. Pregnancy, lactation or child-bearing potential. 7. No insulin therapy and no use of&#xD;
             antioxidants, multivitamin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rehabwerida H Werida, Lecturer</last_name>
    <role>Study Director</role>
    <affiliation>Damanhour University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rehab H Werida, Lecturer</last_name>
    <phone>+201005359968</phone>
    <email>rehabwrieda@pharm.dmu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nashwa EL-Gharabawy, Lecturer</last_name>
    <email>nashwa.elgharbawy@med.tanta.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tanta University Hospital</name>
      <address>
        <city>Tanta</city>
        <state>El-Gharbia</state>
        <zip>31527</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rehab Werida</last_name>
      <phone>01005359968</phone>
      <email>rehabwerida@yahoo.co.uk</email>
    </contact>
    <contact_backup>
      <last_name>Nashwa Elgharbawy, Lecturer</last_name>
      <email>nashwa.elgharbawy@med.tanta.edu.eg</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Panahi Y, Khalili N, Sahebi E, Namazi S, Reiner Ž, Majeed M, Sahebkar A. Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial. Complement Ther Med. 2017 Aug;33:1-5. doi: 10.1016/j.ctim.2017.05.006. Epub 2017 May 29.</citation>
    <PMID>28735818</PMID>
  </results_reference>
  <results_reference>
    <citation>Poolsup N, Suksomboon N, Kurnianta PDM, Deawjaroen K. Effects of curcumin on glycemic control and lipid profile in prediabetes and type 2 diabetes mellitus: A systematic review and meta-analysis. PLoS One. 2019 Apr 23;14(4):e0215840. doi: 10.1371/journal.pone.0215840. eCollection 2019. Retraction in: PLoS One. 2020 May 22;15(5):e0233919.</citation>
    <PMID>31013312</PMID>
  </results_reference>
  <results_reference>
    <citation>Noureldein MH, Abd El-Razek RS, El-Hefnawy MH, El-Mesallamy HO. Fenofibrate reduces inflammation in obese patients with or without type 2 diabetes mellitus via sirtuin 1/fetuin A axis. Diabetes Res Clin Pract. 2015 Sep;109(3):513-20. doi: 10.1016/j.diabres.2015.05.043. Epub 2015 Jun 11.</citation>
    <PMID>26105582</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 22, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Damanhour University</investigator_affiliation>
    <investigator_full_name>Rehab Werida</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Curcumin</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

